Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
STVN Stock Forecast 2026-2027
$18.23
Current Price
$4.98B
Market Cap
Buy 8
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to STVN Price Targets
+75.5%
To High Target of $32.00
+39.9%
To Median Target of $25.50
-4.0%
To Low Target of $17.50
STVN Price Momentum
+2.9%
1 Week Change
+32.6%
1 Month Change
-24.0%
1 Year Change
-9.4%
Year-to-Date Change
-34.9%
From 52W High of $28.00
+41.4%
From 52W Low of $12.89
📊 TOP ANALYST CALLS
Did STVN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Stevanato Group is one of their latest high-conviction picks.
Latest STVN Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, STVN has a bullish consensus with a median price target of $25.50 (ranging from $17.50 to $32.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $18.23, the median forecast implies a 39.9% upside. This outlook is supported by 8 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Paul Knight at Keybanc, projecting a 75.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
STVN Analyst Ratings
8
Buy
2
Hold
0
Sell
STVN Price Target Range
Low
$17.50
Average
$25.50
High
$32.00
Current: $18.23
Latest STVN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for STVN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 6, 2026 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $19.00 |
| Mar 5, 2026 | Citigroup | Patrick Donnelly | Buy | Maintains | $26.00 |
| Mar 5, 2026 | Keybanc | Paul Knight | Overweight | Maintains | $32.00 |
| Dec 2, 2025 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $24.00 |
| Nov 11, 2025 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $26.00 |
| Mar 7, 2025 | UBS | John Sourbeer | Neutral | Maintains | $23.50 |
| Dec 13, 2024 | B of A Securities | Derik De Bruin | Buy | Maintains | $26.00 |
| Dec 13, 2024 | Wolfe Research | Doug Schenkel | Outperform | Initiates | $28.00 |
| Dec 3, 2024 | Morgan Stanley | Tejas Savant | Equal-Weight | Assumes | $23.00 |
| Aug 7, 2024 | Citigroup | Patrick Donnelly | Buy | Maintains | $28.00 |
| Jul 15, 2024 | Morgan Stanley | Drew Ranieri | Equal-Weight | Maintains | $22.00 |
| Apr 22, 2024 | Morgan Stanley | Drew Ranieri | Equal-Weight | Maintains | $30.00 |
| Mar 25, 2024 | Stephens & Co. | Jacob Johnson | Overweight | Reiterates | $38.00 |
| Nov 1, 2023 | Morgan Stanley | Drew Ranieri | Equal-Weight | Maintains | $30.00 |
| Nov 1, 2023 | Jefferies | David Windley | Hold | Downgrade | $29.00 |
| Sep 26, 2023 | Stephens & Co. | Jacob Johnson | Overweight | Initiates | $33.00 |
| Sep 19, 2023 | CJS Securities | Larry Solow | Market Outperform | Initiates | $36.00 |
| Aug 30, 2023 | Keybanc | Paul Knight | Overweight | Maintains | $37.00 |
| Aug 24, 2023 | Morgan Stanley | Drew Ranieri | Equal-Weight | Downgrade | $34.00 |
| Jul 31, 2023 | Wells Fargo | Overweight | Maintains | $N/A |
Stevanato Group S.p.A. (STVN) Competitors
The following stocks are similar to Stevanato Group based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
STVN
Stevanato
mkt cap
4.83B
Stevanato Group S.p.A. (STVN) Financial Data
Stevanato Group S.p.A. has a market capitalization of $4.98B with a P/E ratio of 30.4x. The company generates $1.41B in trailing twelve-month revenue with a 11.7% profit margin.
Revenue growth is +6.6% quarter-over-quarter, while maintaining an operating margin of +14.2% and return on equity of +9.6%.
Valuation Metrics
Market Cap
$4.98B
Enterprise Value
$6.18B
P/E Ratio
30.4x
PEG Ratio
-5.5x
Price/Sales
4.1x
Growth & Margins
Revenue Growth (YoY)
+6.6%
Gross Margin
+30.9%
Operating Margin
+14.2%
Net Margin
+11.7%
EPS Growth
+5.6%
Financial Health
Cash/Price Ratio
+2.2%
Current Ratio
1.6x
Debt/Equity
29.5x
ROE
+9.6%
ROA
+5.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Stevanato Group S.p.A. (STVN) Business Model
About Stevanato Group S.p.A.
What They Do
Provides drug containment and delivery solutions.
Business Model
The company operates through two main segments: Biopharmaceutical and Diagnostic Solutions, and Engineering. It generates revenue by offering a wide range of products, including glass primary packaging and specialized equipment, which support the pharmaceutical and biotechnology industries throughout the drug life cycle, from development to commercial production.
Additional Information
Founded in 1949 and headquartered in Italy, Stevanato Group emphasizes innovation and manufacturing excellence, with a global footprint and production sites in multiple countries. It serves major players in the biopharmaceutical sector, focusing on injectable drugs and diagnostic applications.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
5,521
CEO
Mr. Franco Stevanato
Country
Italy
IPO Year
2021
Website
www.stevanatogroup.comStevanato Group S.p.A. (STVN) Latest News & Analysis
Latest News
Quick Summary
Stevanato Group S.p.A. (NYSE: STVN) reported Q1 2026 revenue of €273.6 million, up 7% year-over-year (10% at constant currency), driven by high-value solutions.
Why It Matters
Stevanato Group's 7% revenue growth signals strong demand for its pharmaceutical solutions, enhancing its market position and potential profitability, which may attract investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Stevanato Group (STVN) reported Q3 earnings of $0.13 per share, surpassing estimates of $0.12 and up from $0.11 per share year-over-year.
Why It Matters
Stevanato Group's earnings beat estimates, indicating stronger performance and growth compared to last year, which can boost investor confidence and potentially increase stock value.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Stevanato Group S.p.A. (NYSE: STVN) will participate in three investor conferences: Bank of America Global Healthcare Conference on May 12 and William Blair Growth Stock Conference on June 2.
Why It Matters
Stevanato Group's participation in key investor conferences signals its active engagement with the investment community, potentially influencing stock interest and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Stevanato (STVN) is not expected to achieve a likely earnings beat in its upcoming report, lacking the necessary key ingredients for success.
Why It Matters
Stevanato's lack of a strong earnings outlook could lead to disappointing results, potentially impacting stock performance and investor sentiment negatively.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
The Conestoga SMid Cap Composite fell -10.24% in Q1, underperforming the Russell 2500 Growth Index at -3.52%. Strong aerospace and defense demand contrasted with Repligen's weaker outlook.
Why It Matters
The Conestoga SMid Cap Composite's underperformance relative to the Russell 2500 Growth Index signals potential risks in mid-cap investments, while sector strength in aerospace may offer opportunities.
Source: Seeking Alpha
Market Sentiment:
Negative
Quick Summary
Stevanato Group S.p.A. (NYSE: STVN) will release its Q1 2026 financial results on May 7, 2026, at 6:30 a.m. EDT, followed by a conference call at 8:30 a.m. EDT.
Why It Matters
Stevanato Group's upcoming financial results can influence stock prices, provide insights into growth and profitability, and impact investor confidence in the pharmaceutical supply chain.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About STVN Stock
What is Stevanato Group S.p.A.'s (STVN) stock forecast for 2026?
Based on our analysis of 12 Wall Street analysts, Stevanato Group S.p.A. (STVN) has a median price target of $25.50. The highest price target is $32.00 and the lowest is $17.50.
Is STVN stock a good investment in 2026?
According to current analyst ratings, STVN has 8 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $18.23. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for STVN stock?
Wall Street analysts predict STVN stock could reach $25.50 in the next 12 months. This represents a 39.9% increase from the current price of $18.23. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Stevanato Group S.p.A.'s business model?
The company operates through two main segments: Biopharmaceutical and Diagnostic Solutions, and Engineering. It generates revenue by offering a wide range of products, including glass primary packaging and specialized equipment, which support the pharmaceutical and biotechnology industries throughout the drug life cycle, from development to commercial production.
What is the highest forecasted price for STVN Stevanato Group S.p.A.?
The highest price target for STVN is $32.00 from Paul Knight at Keybanc, which represents a 75.5% increase from the current price of $18.23.
What is the lowest forecasted price for STVN Stevanato Group S.p.A.?
The lowest price target for STVN is $17.50 from at , which represents a -4.0% decrease from the current price of $18.23.
What is the overall STVN consensus from analysts for Stevanato Group S.p.A.?
The overall analyst consensus for STVN is bullish. Out of 12 Wall Street analysts, 8 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $25.50.
How accurate are STVN stock price projections?
Stock price projections, including those for Stevanato Group S.p.A., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 9, 2026 2:20 PM UTC